Cargando…

Initiation of Antiviral Treatment in SARS‐CoV2: Modeling Viral Dynamics and Drug Properties

Detalles Bibliográficos
Autores principales:	Rosenbloom, Daniel Scholes, Zhao, Ping, Sinha, Vikram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405045/ https://www.ncbi.nlm.nih.gov/pubmed/32700405 http://dx.doi.org/10.1002/psp4.12550

Ejemplares similares

Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load
por: Gonçalves, Antonio, et al.
Publicado: (2020)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

New emerging SARS-CoV-2 variants and antiviral agents
por: Vitiello, A., et al.
Publicado: (2023)

Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide
por: Stefano, George B., et al.
Publicado: (2020)

Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents
por: Ayaz, Sameer, et al.
Publicado: (2020)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients
por: Parums, Dinah V.
Publicado: (2022)

How Antivirals Might be Linked to the Emergence of New Variants of SARS-CoV-2
por: Mehdizadeh, Ali Reza, et al.
Publicado: (2021)

Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development
por: Cao, Youfang, et al.
Publicado: (2021)

Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus
por: Terrier, Olivier, et al.
Publicado: (2021)

Special Issue “Advances in Antiviral Agents against SARS-CoV-2 and Its Variants”
por: Esposito, Francesca, et al.
Publicado: (2023)

SARS‐CoV‐2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy
por: Zhang, Shengyuan, et al.
Publicado: (2023)

Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures
por: Peng, Lihong, et al.
Publicado: (2021)

Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection
por: Khezri, Mohammad Rafi, et al.
Publicado: (2021)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

The emergence, dynamics and significance of SARS-CoV-2 variants
por: COLSON, Philippe, et al.
Publicado: (2022)

The viral phoenix: enhanced infectivity and immunity evasion of SARS-CoV-2 variants
por: Choi, Hosoon, et al.
Publicado: (2021)

How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules
por: Focosi, Daniele, et al.
Publicado: (2023)

Eosinophils in antiviral immunity and (perhaps) a benefit of having asthma during the SARS-CoV2 pandemic
por: Eid, Ryan, et al.
Publicado: (2021)

Modeling the viral dynamics of SARS-CoV-2 infection
por: Wang, Sunpeng, et al.
Publicado: (2020)

Viral dynamics of SARS-CoV-2 in immunocompromised patients
por: Utzon, Andrea N., et al.
Publicado: (2023)

Systematic Review and Patient‐Level Meta‐Analysis of SARS‐CoV‐2 Viral Dynamics to Model Response to Antiviral Therapies
por: Gastine, Silke, et al.
Publicado: (2021)

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

Viral pandemics and oral health: Lessons learned from HIV to SARS-CoV-2
por: Patton, Lauren L.
Publicado: (2021)

Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?
por: Santos, Igor de Andrade, et al.
Publicado: (2020)

Molecular Investigation of SARS–CoV-2 Proteins and Their Interactions with Antiviral Drugs
por: Calligari, Paolo, et al.
Publicado: (2020)

SARS‐CoV‐2–host proteome interactions for antiviral drug discovery
por: Liu, Xiaonan, et al.
Publicado: (2021)

Inferring SARS-CoV-2 functional genomics from viral transcriptome with identification of potential antiviral drugs and therapeutic targets
por: Pan, Xu, et al.
Publicado: (2021)

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis
por: Cevik, Muge, et al.
Publicado: (2021)

The practical challenges of making clinical use of the quantitative value for SARS-CoV-2 viral load across several dynamics
por: Mathers, Amy J
Publicado: (2020)

Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2
por: Chen, Na, et al.
Publicado: (2022)

Unexplored Potential of Essential Oils in Reducing SARS-CoV-2 Viral Load in Dental Clinics
por: Dagli, Namrata
Publicado: (2021)

Post-Viral Olfactory Loss: What We Learned from the SARS-CoV-2 Pandemic
por: Vaira, Luigi Angelo, et al.
Publicado: (2022)

Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses
por: Machado-Vieira, Rodrigo, et al.
Publicado: (2021)

Antiviral properties of whey proteins and their activity against SARS-CoV-2 infection
por: Gallo, Valentina, et al.
Publicado: (2022)

In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age
por: Lieberman, Nicole A. P., et al.
Publicado: (2020)

Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro
por: Zhang, Leike, et al.
Publicado: (2020)

Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies
por: Watson, James A., et al.
Publicado: (2022)

Inhibition of SARS-CoV2 viral infection with natural antiviral plants constituents: An in-silico approach
por: Das, Kuntal, et al.
Publicado: (2023)

SARS-CoV-2 viral dynamics in non-human primates
por: Gonçalves, Antonio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e3tj964r7mamu7o90jc8sat3fs